ValiRx PLC on Monday said its wholly-owned subsidiary, Inaphaea BioLabs Ltd, has entered into a collaborative services agreement with Agility Life Sciences Ltd.

ValiRx is an Essex, England-based life science company focused on early-stage cancer therapeutics and women’s health. Its shares were up 2.3% to 7.01 pence each in London early Monday.

‘The collaborative services agreement recognises the synergy between Inaphaea’s growing capabilities as a translational contract research organisation and Agility’s capabilities for formulation development and optimisation, pre-formulation studies and analysis,’ ValiRx said.

The company explained that service users of Inaphaea will be able to benefit from Agility’s capabilities in a single service contract with Inaphaea and similarly, service users of Agility will be able to access Inaphaea’s capabilities through their service contract with Agility.

This will enable a coherent, single point of contact for service users to formulate and test their drug candidates, it added.

ValiRx noted that it has already run two projects with Agility.

Chief Executive Officer Suzy Dilly said: ‘In a comparative manner to our collaborative services agreement with Physiomics announced in April 2023, this new arrangement with Agility further expands the Inaphaea service capability. This agreement is very much reciprocal, and we expect to be able to offer our services to Agility customers just as much as offering their services to ours.’

Copyright 2023 Alliance News Ltd. All Rights Reserved.